Passage Bio revises Remix merger to two-step structure
Passage Bio amended its merger agreement with Remix Therapeutics to use a two-step structure intended to qualify as a tax-free reorganization, while preserving prior economics, closing conditions and the Dec. 24, 2026 outside date.
Passage Bio amended its merger agreement with Remix Therapeutics to implement a two-step structure intended to qualify as a tax-free reorganization while preserving prior economics, closing conditions, and the Dec.
24, 2026 outside date.
In tandem, Remix and investors amended the concurrent private…